STERIS Stock Forecast, Price & News

STERIS's stock was trading at $145.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, STE shares have increased by 33.3% and is now trading at $193.66.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for STERIS or view MarketBeat's top 5 stock picks.

Wall Street analysts have given STERIS a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but STERIS wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

STERIS is scheduled to release its next quarterly earnings announcement on Monday, February 8th 2021.
View our earnings forecast for STERIS.

STERIS plc (NYSE:STE) issued its earnings results on Monday, November, 2nd. The medical equipment provider reported $1.48 EPS for the quarter, beating the consensus estimate of $1.27 by $0.21. The medical equipment provider earned $756.13 million during the quarter, compared to analysts' expectations of $719.54 million. STERIS had a return on equity of 16.24% and a net margin of 13.69%. The company's quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.32 earnings per share.
View STERIS's earnings history.

STERIS declared a quarterly dividend on Monday, November 2nd. Stockholders of record on Tuesday, November 24th will be paid a dividend of $0.40 per share on Friday, December 18th. This represents a $1.60 annualized dividend and a dividend yield of 0.83%. The ex-dividend date is Monday, November 23rd.
View STERIS's dividend history.

4 equities research analysts have issued 12 month price objectives for STERIS's shares. Their forecasts range from $200.00 to $200.00. On average, they anticipate STERIS's share price to reach $200.00 in the next year. This suggests a possible upside of 3.3% from the stock's current price.
View analysts' price targets for STERIS.

STERIS saw a drop in short interest during the month of October. As of October 30th, there was short interest totaling 907,000 shares, a drop of 21.8% from the October 15th total of 1,160,000 shares. Based on an average daily volume of 409,900 shares, the days-to-cover ratio is presently 2.2 days.
View STERIS's Short Interest.

Some companies that are related to STERIS include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Hologic (HOLX), Teleflex (TFX), Insulet (PODD) and Varian Medical Systems (VAR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other STERIS investors own include Johnson & Johnson (JNJ), The Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA) and Medtronic (MDT).

STERIS trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."

STERIS's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.87%), WCM Investment Management LLC (7.61%), State Street Corp (4.37%), Massachusetts Financial Services Co. MA (3.54%), William Blair Investment Management LLC (1.46%) and ArrowMark Colorado Holdings LLC (1.19%). Company insiders that own STERIS stock include Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Kathleen Bardwell, Loyal W Wilson, Michael B Wood, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard C Breeden, Richard Martin Steeves and Walter M Rosebrough Jr.
View institutional ownership trends for STERIS.

STE stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Morgan Stanley, Great Lakes Advisors LLC, Fisher Asset Management LLC, First Trust Advisors LP, AXA S.A., Robeco Institutional Asset Management B.V., and State Street Corp. Company insiders that have sold STERIS company stock in the last year include Cary L Majors, Daniel A Carestio, John Adam Zangerle, Karen L Burton, Mohsen Sohi, Richard C Breeden, Richard Martin Steeves, and Walter M Rosebrough Jr.
View insider buying and selling activity for STERIS.

STE stock was bought by a variety of institutional investors in the last quarter, including Polar Capital LLP, Polar Capital LLP, Massachusetts Financial Services Co. MA, WCM Investment Management LLC, Williams Jones Wealth Management LLC., JPMorgan Chase & Co., Great West Life Assurance Co. Can, and Great West Life Assurance Co. Can.
View insider buying and selling activity for STERIS.

Shares of STE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of STE stock can currently be purchased for approximately $193.66.

STERIS has a market capitalization of $16.52 billion and generates $3.03 billion in revenue each year. The medical equipment provider earns $407.61 million in net income (profit) each year or $5.64 on an earnings per share basis. STERIS employs 13,000 workers across the globe.

The official website for STERIS is www.steris.com.

STERIS's mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider can be reached via phone at 353-1232-2000 or via email at [email protected]